Sinopharm group: Six listed companies speed up the adjustment when the reform is in progress

As the only Chinese pharmaceutical enterprise that has entered the list of the world's top 500 for four consecutive years, the China Pharmaceutical Group directly managed by the state owned assets supervision and Administration Commission of the State Council is the largest pharmaceutical and health industry group in China with the most complete industrial chain and the strongest comprehensive strength It focuses on the distribution, retail, R & D and production of health-related products such as preventive treatment and diagnostic care It has 11 wholly-owned or holding subsidiaries and 6 listed companies (Sinopharm holding, Sinopharm holding, Sinopharm congruity, Tiantan biology, Hyundai pharmaceutical, and Chinese traditional medicine listed in Hong Kong stock) Among them, Sinopharm holdings is the commercial platform, Tiantan biology is the biological medicine platform, modern pharmaceutical is the chemical medicine platform, Chinese traditional medicine is the traditional Chinese medicine platform, and Sinopharm is the pharmaceutical commercial and retail platform In 2016, pharmaceutical policies were introduced frequently, which brought benefits and impacts to pharmaceutical enterprises simultaneously Combined with the layout of six listed companies, we may see the Countermeasures of Sinopharm, a giant Sinopharm Holdings: to build a vertical e-commerce platform, Sinopharm holdings is the largest wholesaler and retailer of drugs and health care products in China It is mainly engaged in pharmaceutical distribution business It is one of the only three authorized narcotic distributors in China The market value of the company is the fourth largest global distribution enterprise In 2016, Sinopharm realized an operating revenue of 258.38 billion yuan, an increase of 12.99% year on year, and continued to maintain the position of the largest pharmaceutical company with market value of Hong Kong shares In the first quarter of 2017, according to the company's consolidated income statement, Sinopharm holdings achieved a total operating revenue of 68.425 billion, an increase of 8.5% year-on-year; the net profit attributable to the owners of the parent company was 1.252 billion In the field of pharmaceutical distribution, Sinopharm Holdings has formed an integrated pharmaceutical supply chain, with its distribution network covering 31 provinces, municipalities and autonomous regions in China, with a total number of 251 logistics outlets In the field of pharmaceutical retail, Sinopharm's stores cover 18 provinces and cities, with more than 3500 retail pharmacies, leading the industry in scale With the gradual implementation of the two vote system, it is expected that a large-scale reshuffle will take place in the pharmaceutical circulation industry in the future to accelerate the survival of the fittest and integration of the industry, and the national leading distribution enterprises, including Sinopharm holdings, kyushutong, China Resources pharmaceutical, etc., will have a greater competitive advantage In addition, relying on the existing advantageous resources, Sinopharm is actively developing e-commerce In the future, it will continue to promote the development of medical e-commerce, build a vertical e-commerce service platform integrating B2B, B2C, o2o and other services, and provide "medical + pharmaceutical" full ecological services Sinopharm Co., Ltd.: asset restructuring, optimization of structure Sinopharm Co., Ltd takes direct drug sales as its main business, faces medical customers, retail end customers and commercial customers, and plays a leading role in the pharmaceutical trading business of jute In order to solve the problem of horizontal competition, in February 2016, Sinopharm suspended trading, officially launched major asset restructuring, and integrated four pharmaceutical commercial assets in Beijing within the national control system on the platform of Sinopharm According to the 2016 annual report, the revenue in 2016 was 13.39 billion yuan, an increase of 10.93% year on year The core business of Sinopharm is still the anesthetic market, which will accelerate the transformation and upgrading, and consolidate the market share of anesthetic Consistency of Sinopharm: to create a new growth point of distribution, consistency of Sinopharm is the capital operation platform of Sinopharm group's retail business, positioning the development strategy of "national retail + Guangdong, Guangdong and Guangdong distribution + industrial investment" In the field of distribution, Sinopharm's pharmaceutical distribution business has achieved the first scale in Guangdong and Guangdong regions; in the field of retail, Sinopharm's national pharmacy ranks the first in terms of national sales scale, and is one of the few domestic enterprises with national direct drug retail network In 2016, Sinopharm consistently achieved revenue of RMB 41.248 billion, an increase of 9.07% year-on-year; the net profit attributable to shareholders of listed companies was RMB 1.187 billion, an increase of 27.92% year-on-year, and the growth trend continued Among them, the unified distribution business of Sinopharm achieved an operating revenue of 31.136 billion yuan, a year-on-year increase of 9.9%, and a net profit of 604 million yuan, a year-on-year increase of 10.15%; the retail business of Sinopharm achieved an operating revenue of 9.109 billion yuan, a year-on-year increase of 13.99%; and a net profit of 223 million yuan, a year-on-year increase of 60.93% In 2017, Sinopharm will consistently tap new advantages, achieve new breakthroughs in herbal pieces and devices, and create a new profit growth point for distribution Build logistics around the intelligent supply chain and establish a distribution system for service end consumers Tiantan Bio: it is the only bio pharmaceutical platform of Sinopharm group to divest vaccine business and code blood products Since March this year, Tiantan biology has gradually stripped vaccine business and added blood products business Its net profit has increased 148 times year-on-year, and it has become the leader of blood products enterprises According to the 2016 annual report of Tiantan biology, the company's vaccine business has been transferred to the controlling shareholder Zhongsheng Co., Ltd as a whole, its main business will be focused on the production, sales and R & D of blood products At the same time, Zhongsheng Co., Ltd is one of the blood product business assets that have horizontal competition with the company, i.e 80% equity of Guizhou Zhongtai Co., Ltd After the completion of asset integration of blood products business, the number of plasma collection stations and the amount of plasma collection owned by the listed company will be the first in China Main financial data of Tiantan biology in 2016 In the first quarter of 2017, Tiantan bio's revenue was 523 million yuan, with a net profit of 99.58 million yuan, up 45.17% and 14829.87% year-on-year, respectively The blood products sector benefited from the strong market demand, and the product sales continued to increase The production of the prevention products of mumps series vaccine gradually picked up, and the oral type I and III live attenuated poliomyelitis vaccine (human diploid cells) was listed, which greatly increased the company's revenue, The loss situation improved year on year In the 2017 version of the medical insurance catalog, except for hepatitis B human immunoglobulin (including intramuscular injection and intravenous injection products), other blood products in production of Tiantan biology have been included in the medical insurance catalog The domestic blood products market has been in a state of short supply and warm industrial policies Therefore, in 2016, various blood products enterprises made frequent efforts As the only central enterprise, Tiantan biology developed rapidly and the market continued to rise Modern pharmacy: the pain of medical reform, asset restructuring according to the integration strategy of Sinopharm group's chemical industry sector, modern pharmacy is positioned in the chemical industry platform of Sinopharm group, focusing on five areas of anti infective drugs, anti-tumor drugs, narcotic psychotropic drugs, cardiovascular and cerebrovascular drugs and big health, and building a more competitive product line in the market However, under the impact of "anti restriction and needle restriction", in 2016, the overall operation of modern pharmaceutical industry was lower than the industry average level, with the operating revenue of 9.13 billion yuan, an increase of 1.54% year on year, the total profit of 1.04 billion yuan, a decrease of 1.95% year on year, and the net profit attributable to the parent company of 477 million yuan, a decrease of 10.01% year on year In 2016, modern pharmaceutical implemented a major asset restructuring, which is the most powerful in history The company purchased 11 equity assets including 100% equity of Sinopharm Group Industry Co., Ltd and 100% equity of Sinopharm group Weiqida Pharmaceutical Co., Ltd and operational assets of Pingshan base by issuing shares and paying cash At present, the first stage of asset integration has been completed After the major assets reorganization, modern pharmaceutical has 17 secondary enterprises and 11 tertiary enterprises, and its product line has been greatly expanded In February 2017, the Ministry of human resources and social security issued a new version of the national medicine catalog A total of 40 products of modern pharmaceutical and its subsidiaries were newly included in the new version of the national medical insurance catalog, and 14 products were withdrawn from the medical insurance catalog Chinese traditional medicine: the layout of Chinese traditional medicine granules and pieces of Chinese traditional medicine is the only Chinese traditional medicine listing platform of Sinopharm group In 2012, Chinese traditional medicine listed in Yingtian Hong Kong by backdoor, acquired Chinese traditional medicine assets continuously, and acquired 87.3% equity of Jiangyin Tianjiang (the largest Chinese traditional medicine formula granule company in China) in 2015 Its subsidiaries include Sinopharm Dezhong (Foshan) Pharmaceutical Co., Ltd., Sinopharm Tongjitang (Guizhou) Pharmaceutical Co., Ltd., and Sinopharm Guangdong Global Pharmaceutical Co., Ltd Thanks to the fact that 2016 was the first full year of merger after Tianjiang pharmaceutical was acquired, the turnover in 2016 reached 6.53 billion yuan, up 76.12% from 3.71 billion yuan in 2015 In 2016, the state stepped up efforts to promote the development of the traditional Chinese medicine industry Chinese traditional medicine comprehensively arranged the production base of traditional Chinese medicine formula granules and the processing base of herbal pieces, built eight extraction bases of traditional Chinese medicine and the production base of traditional Chinese medicine formula granules covering multiple provinces After the 2017 new medical insurance catalog was adjusted, 282 proprietary Chinese medicines including 26 exclusive products were included.